Verici Dx’s Post

Aug 31, 2024, 11:09 Edward D. Esplin: Clinician Responses to #Germline #GeneticTesting in #ProstateCancer Management Edward D. Esplin, Clinical Geneticist at Invitae, shared on X: “Up to 17% of #prostatecancer patients have PGVs with #germlinetesting 36% of universally tested PC #patients had positive health outcomes 2/2 #genetictesting results Neal Shore et al. ‘This study supports #universal #germline #genetictesting for #patients with #prostatecancer, and it demonstrates the clinical utility of #germline #genetictesting results—both positive and negative—for…the care of #patients and their families.’” https://lnkd.in/g_jjfT5x American Urological Association https://lnkd.in/gYvBPPiE OncoDaily #access #reducedisparities #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention #AI #precisioninterpretation Invitae Labcorp

This review explores the integration of #functionalgenomics and #multiomics approaches in #neuromusculardisease diagnosis, aiming to increase the proportion of patients receiving #moleculardiagnoses. https://lnkd.in/d73J82kX

When assessing biomarkers for post-kidney transplant patients, one phrase has been constant when it comes to acute rejection: Rule out. Here at Verici Dx we invite you to consider the benefits of Balanced Accuracy, to be able to rule in and rule out. Balanced accuracy is the compass that guides us towards better patient outcomes. It's the delicate balance between sensitivity and specificity and PPV and NPV allowing you to make informed decisions with confidence. Why is it crucial? Because in the post-transplant journey, every decision matters. We need biomarkers that identify potential issues accurately, minimizing both false positives and false negatives. Tutivia delivers an odds ratio of 5.74 allowing for clear stratification between high and low risk which offers clinicians a trusted tool in their clinical practice. Balanced accuracy empowers clinicians to tailor treatments, reduce unnecessary interventions, and offer personalized care. It's about optimizing the delicate balance of accuracy in medicine. To learn how Tutivia offers balanced accuracy for post-kidney transplant providers and patients, visit our website: https://lnkd.in/ewzAaJzK #BalancedAccuracy #TutiviaDelivers #ClarityEvenEarly

When listening to the voice of #eHCPs in #multiplemyeloma in US and Canada we observed a significant focus amongst HCPs towards adopting a more #patientcentric approach. eHCPs considered patient factors such as refractory status and transplant eligibility when sequencing treatment. Read more here https://bit.ly/4aqZSC8 #MMsm #myeloma

🚀 Exciting advancements in clinical trials! AnzuBridge's Media Capture and Review technology is transforming the way we approach the cure and treatment of various diseases. Revolutionizing clinical trials with advanced media capture to accelerate approvals, improve compliance, and enhance efficiency. Our technology makes it easier to capture and review videos of subjects performing various actions, which is critical for: 🧠 Neurodegenerative Diseases 💪 Muscular Disorders 🧬 Rare Genetic Conditions 👶 Pediatric Conditions ❤️ Cardiovascular Diseases 👁️ Vision and Hearing Disorders 🩺 Movement Disorders 🎗️ Oncology Trials With features like bookmarking and clipping, stakeholders and regulators can efficiently review and fast-track the approval of clinical trials, bringing treatments to patients faster. Discover how AnzuBridge can enhance your clinical trials today! 👉 Book a demo: https://lnkd.in/ebhkAnbV #NeurodegenerativeDiseases #MuscularDisorders #RareGeneticConditions #PediatricConditions #CardiovascularDiseases #VisionDisorders #HearingDisorders #MovementDisorders #OncologyTrials #ClinicalTrials #MedicalInnovation #HealthcareTech #RegulatoryApproval #PatientCare #MedicalResearch #Biotech #HealthTech #AnzuBridge #ClinicalResearch #LifeSciences

𝐂𝐚𝐧𝐜𝐞𝐫-𝐟𝐨𝐜𝐮𝐬𝐞𝐝 𝐆𝐞𝐧𝐞𝐭𝐢𝐜 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐒𝐞𝐫𝐯𝐢𝐜𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞, 𝐒𝐡𝐚𝐫𝐞 & 𝐓𝐫𝐞𝐧𝐝𝐬 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 2024-2031 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐃𝐞𝐦𝐨 𝐑𝐞𝐩𝐨𝐫𝐭, 𝐄𝐱𝐜𝐞𝐥 𝐏𝐢𝐯𝐨𝐭 𝐚𝐧𝐝 𝐓𝐨𝐂: https://lnkd.in/g4GAcqcR The #Cancerfocused #GeneticTesting Service Market Size is valued at USD 7.82 billion in 2023 and is predicted to reach USD 14.41 billion by the year 2031 at an 8.2% CAGR during the forecast period for 2024-2031. ▪ 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐫𝐞: ▪ Cleveland Clinic ▪ Fortis Healthcare ▪ KIMS Hospitals ▪ Rush University Medical Center ▪ The Women's Board of The Johns Hopkins Hospital ▪ Bridgeport Hospital ▪ Greenwich Hospital ▪ Lawrence + Memorial Hospital ▪ Westerly Hospital ▪ Yale New Haven Hospital ▪ Northeast Medical Group #GeneticTesting #CancerDiagnostics #DNATesting #ChromosomeTesting #BiochemicalTesting #BreastCancer #ColorectalCancer #LungCancer

Tutivia: Defining Early Acute Rejection Prediction! In our recently published validation study, Tutivia has demonstrated its incredible potential as an early predictor of acute rejection (AR) post-kidney transplant: Of the 44 for cause biopsies, 35 were performed within 60-days post-transplant. 24 showed acute rejection during this time and 83% (20) with AR exhibited a high-risk Tutivia score. Tutivia achieved a Positive Predictive Value (PPV) of 0.75 and a Negative Predictive Value (NPV) of 0.63 for clinical rejection identified in for-cause biopsies. This groundbreaking data underscores Tutivia's role in revolutionizing transplant care, offering actionable data and defining early. #TutiviaDelivers #ClarityEvenEarly https://lnkd.in/ewzAaJzK

[INNOVATION UPDATE] Donanemab to Treat Early Alzheimer’s disease Toxic accumulations of amyloid-beta (Aβ) protein in the brain, often called plaques, are thought to be key contributors to Alzheimer’s disease (AD) pathology. Donanemab (Kisunla) is a monoclonal antibody designed to bind to Aβ plaques and promote their clearance from the brain, thus slowing cognitive decline. Donanemab was approved by the U.S. Food and Drug Administration to treat patients with early symptomatic AD, including mild cognitive impairment as well as the mild dementia stage of AD, who have confirmed amyloid pathology. Want to learn more about this novel therapy? View the latest Emerging Health Care Innovation Brief: Emerging Healthcare Innovation Brief Volume 2 - Issue 15 (https://hubs.la/Q02KCv540) #alzheimersdisease #earlyalzheimers #dementia #neurology#patientcare #healthcare #innovation #horizonscanning #ecri

The National Institutes of Health announced four Phase 2 winners of the Neuromod Prize, a $9.8 million competition to accelerate the development of targeted neuromodulation therapies. The winning teams will each receive $1 million and an exclusive invitation to join Phase 3. The competition, designed and produced by Luminary Labs, is advancing neuromodulation solutions and will bring them much closer to having tangible patient impact, offering new hope to millions of patients battling chronic or acute diseases. Learn more about the winners’ solutions and find out what comes next in Phase 3. https://lnkd.in/en7Nes9g #OpenInnovation #LabReport #NeuromodPrize

The transformative power of precision medicine is improving healthcare outcomes and managing costs. Precision medicine's focus on individual biology enables accurate disease diagnosis and treatment. At Pepper Bio, we're aligned with this paradigm, diligently working to tackle 'untreatable' diseases. Our advanced computational platform is key in this endeavor, as we personalize treatments for complex conditions like cancer and rare diseases. Jennifer Levin Carter MD, MPH, MBA.’s deeper insights into precision medicine’s impact can be found here: https://lnkd.in/gnhNhEX7 #PrecisionMedicine #Biotech #DrugDiscovery